The Food and Drug Administration considers that postpartum depression or postpartum depression (PPD) can be similar to other forms of clinical depression, as its symptoms can include sadness, loss of energy, and suicidal ideation, decreased ability to feel pleasure or cognitive impairment.
According to research, one in seven women in the United States experiences symptoms of postpartum depression.
“Postpartum depression is a serious and life-threatening condition in which women feel sad, guilty, useless – even, in severe cases, thoughts of hurting themselves. harm or harm their child,” said Tiffany Farchione, chief of psychiatry at the FDA Center. for Drugs. Evaluation and research.
“And, because postpartum depression can disrupt the mother-child relationship, it can also affect a child’s physical and emotional development.
The Food and Drug Administration has approved “zuranolone” to be used as a pill to treat postpartum depression, becoming a potential alternative to the only treatment. Existing is done by intravenous injection. The drug, sold under the brand name ‘Zurzuvae’, has been recommended by the FDA for patients to take as a tablet once daily for two weeks.
According to drugmakers Sage Therapeutics and Biogen, the drug will be available on the market by the end of this year.
Meanwhile, common side effects of the drug include drowsiness, dizziness, diarrhea, fatigue, colds and urinary tract infections, the BBC reported.
